Report copyright - Trial record 1 of 1 for: Endure (ENDURE-CML-IX) · in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5,
Please pass captcha verification before submit form